<DOC>
	<DOC>NCT01196728</DOC>
	<brief_summary>The primary objective of this study is to assess the safety and tolerability of the Glucagon-like peptide-1 (GLP-1) peptide analogue CM3.1-AC100 after single subcutaneous (sc) doses in patients with T2DM.</brief_summary>
	<brief_title>Single-centre, Randomised, Double-blind, Placebo-controlled, Four-way Crossover Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Single Doses of CM3.1-AC100 in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>1. Provision of signed and dated informed consent prior to any study specific procedures 2. Type 2 diabetes mellitus patient, diagnostically confirmed since at least 6 months 3. Male or female patient aged 18 to 75 years at screening, both inclusive 4. BMI &gt;22 to â‰¤40 kg/m2 at screening 1. Type 1 diabetes mellitus, diabetes that is a result of pancreatic injury, or secondary forms of diabetes, eg Cushings's syndrome and acromegaly 2. Fasting Cpeptide &lt; 500 pM at screening 3. Acute gastrointestinal symptoms at the time of screening and/or Day 1 4. Any clinically relevant history or the presence of cardiovascular, bronchopulmonary, gastrointestinal or neurological diseases inclusive history of chronic pancreatitis or acute pancreatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2010</verification_date>
</DOC>